<DOC>
	<DOCNO>NCT00402194</DOCNO>
	<brief_summary>A study 12 week ' treatment losartan placebo , test hypothesis RAS inhibition improve insulin ' vascular action therefore improve insulin sensitivity skeletal muscle .</brief_summary>
	<brief_title>Treating Endothelium Restore Insulin Sensitivity</brief_title>
	<detailed_description>Recent study suggest effect cardiovascular therapy prevent diabetes remain unexplained . We hypothesize therapy improve vascular endothelial function allow improved action insulin vasculature , comprise significant portion insulin 's metabolic action . We therefore propose measure insulin-mediated glucose disposal insulin-mediated vasodilation 12 week ' therapy Losartan ( angiotensin receptor blocker ) placebo , randomize design . Subjects include 28 subject impair glucose tolerance , generally accompany insulin resistance impair vascular function . With number participant 90 % chance show statistically significant clinically meaningful effect insulin leg vascular resistance , even high chance show difference insulin 's metabolic effect . Exclusion criterion include frank hypertension , diabetes , hypercholesterolemia , biochemical contraindication losartan therapy . The primary endpoint statistical analysis invasive measure insulin-stimulated endothelial function . We anticipate improvement vascular metabolic measure insulin action follow Losartan therapy change untreated baseline follow placebo .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Healthy Age 2055 Male female Obese , define Males : BMI &gt; 28 &gt; 30 % fat DEXA scan Bod Pod ; Females : BMI &gt; 30 &gt; 33 % fat DEXA scan Bod Pod Weight stable least 4 month Diabetes mellitus ( ADA criterion ) Age &lt; 20 &gt; 55 yr Blood pressure &gt; 160/90 &lt; 90/65 mmHg Total cholesterol &gt; 240 LDL cholesterol &gt; 160 mg/dL Baseline elevation AST ALT &gt; 3X ULN Baseline elevation creatinine &gt; 1.6 ng/mL Unexplained baseline elevation creatine kinase &gt; 3X ULN Concurrent significant chronic medical illness include , limited , human immunodeficiency virus infection , Syphilis , hepatitis B infection , hepatitis C infection Pregnancy Known hypersensitivity intolerance study agent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Insulin resistance</keyword>
	<keyword>Impaired glucose tolerance</keyword>
	<keyword>pre-diabetes</keyword>
</DOC>